09-Nov-2026Press ReleaseMorepen enters U.S. prescription generics market, building on its established API strengthsDownload PDF
28-Sept-2026Press ReleaseMorepen strengthens integrated CDMO capabilities with first U.S. ANDA submissionDownload PDF
04-Aug-2026Press ReleaseMorepen clocks highest-ever quarterly revenue and earnings in Q1’FY27Download PDF
01-Jul-2026Press ReleaseMorepen starts commercial supplies under its ₹ 825 Crore CDMO mandateDownload PDF
27-May-2026Press ReleaseMorepen Labs Q4 Net Profit Rises 69%; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10% to the shareholders for FY26Download PDF
17-Apr-2026Press ReleaseMorepen Secures Fourth Consecutive USFDA Inspection with Zero Observations (NIL 483)Download PDF
23-Feb-2026Press ReleaseMorepen Bags ₹825 Crore Global Deal; Expands Into High-Growth CDMO Segment.Download PDF
13-Nov-2025Press ReleaseKids’ Health and Screen Habits: Dr. Morepen Sparks a National Conversation on the Need to Play MoreDownload PDF
13-May-2025Press ReleaseMorepen Board Proposed Dividend After 23 Years Scores Highest PAT of ₹118 Crore in FY25Download PDF